Literature DB >> 23891383

A rapid method for the determination of perfluoroalkyl substances including structural isomers of perfluorooctane sulfonic acid in human serum using 96-well plates and column-switching ultra-high performance liquid chromatography tandem mass spectrometry.

Samira Salihovic1, Anna Kärrman, Gunilla Lindström, P Monica Lind, Lars Lind, Bert van Bavel.   

Abstract

To facilitate high-throughput analysis suitable for large epidemiological studies we developed an automated column-switching ultra-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for determination of perfluorocarboxylic acids (PFCAs; C5, C6, C7, C8, C9, C10, C11, C12, and C13), perfluoroalkyl sulfonic acids (PFSAs; C4, C6, C8, and C10), perfluorooctane sulfonamide (PFOSA), and five groups of structural perfluorooctane sulfonic acid (PFOS) isomers in human serum or plasma. The analytical procedure involves rapid protein precipitation using 96-well plates followed by an automated sample clean-up using an on-line trap column removing many potentially interfering sample components while through the mobile phase gradient the target analytes are eluted onto the analytical column for further separation and subsequent mass detection. The method was linear (R(2)<0.995) at concentrations ranging from 0.01 to 60ngmL(-1) with method detection limits ranging between 0.01 and 0.17ngmL(-1) depending on the analyte. The developed method was precise, with repeatability (n=7) and reproducibility (n=103) coefficients of variation between 2% and 20% for most compounds including PFOS (2% and 8%) and its structural isomers (2-6% and 4-8%). The method was in conformity with a standard reference material. The column-switching HPLC-MS/MS method has been successfully applied for the determination of perfluoroalkyl substances including structural PFOS isomers in human plasma from an epidemiological study.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Column-switch; Human blood; PFOA; PFOS; Perfluoroalkyl substances; Structural isomers

Mesh:

Substances:

Year:  2013        PMID: 23891383     DOI: 10.1016/j.chroma.2013.07.026

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  6 in total

1.  Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly.

Authors:  Lars Lind; Björn Zethelius; Samira Salihovic; Bert van Bavel; P Monica Lind
Journal:  Diabetologia       Date:  2013-12-14       Impact factor: 10.122

2.  Utilization of a NIST SRM: a case study for per- and polyfluoroalkyl substances in NIST SRM 1957 organic contaminants in non-fortified human serum.

Authors:  Alix E Rodowa; Jessica L Reiner
Journal:  Anal Bioanal Chem       Date:  2021-03-02       Impact factor: 4.142

3.  A sensitive approach for simultaneous quantification of carbonyl and hydroxyl steroids using 96-well SPE plates based on stable isotope coded-derivatization-UPLC-MRM: method development and application.

Authors:  Chuanxin Liu; Xue Sheng; Yuming Wang; Jia Yin; Wei Huang; Yunshuang Fan; Yubo Li; Yanjun Zhang
Journal:  RSC Adv       Date:  2018-05-30       Impact factor: 3.361

4.  Changes in plasma levels of perfluoroalkyl substances (PFASs) are related to increase in carotid intima-media thickness over 10 years - a longitudinal study.

Authors:  P Monica Lind; Samira Salihovic; Jordan Stubleski; Anna Kärrman; Lars Lind
Journal:  Environ Health       Date:  2018-07-03       Impact factor: 5.984

5.  Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Samira Salihović; Alex M Dickens; Ida Schoultz; Frida Fart; Lisanna Sinisalu; Tuomas Lindeman; Jonas Halfvarson; Matej Orešič; Tuulia Hyötyläinen
Journal:  Anal Bioanal Chem       Date:  2019-11-23       Impact factor: 4.142

6.  Development and validation of an LC-MS/MS method for the quantitation of 30 legacy and emerging per- and polyfluoroalkyl substances (PFASs) in human plasma, including HFPO-DA, DONA, and cC6O4.

Authors:  Gianfranco Frigerio; Simone Cafagna; Elisa Polledri; Rosa Mercadante; Silvia Fustinoni
Journal:  Anal Bioanal Chem       Date:  2021-12-15       Impact factor: 4.142

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.